MedTrace Logo

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

NCT05298670 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-03-20

No results posted yet for this study

Summary

This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.

Conditions

Interventions

DRUG

MetFORMIN 1000 Mg Oral Tablet

Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.

DRUG

Interferon beta-1a

Disease Modifying Therapies (DMTs)

Sponsors & Collaborators

  • German University in Cairo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2023-02-28
Completion
2023-03-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05298670 on ClinicalTrials.gov